These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2388646)

  • 21. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The apomorphine test in Parkinson's disease: diagnostic value].
    Linazasoro G
    Neurologia; 1993 Nov; 8(9):288-90. PubMed ID: 8297620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.
    Hsu A; Togasaki DM; Bezard E; Sokoloff P; Langston JW; Di Monte DA; Quik M
    J Pharmacol Exp Ther; 2004 Nov; 311(2):770-7. PubMed ID: 15226382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditioning the placebo response in the rotational model of Parkinson's disease.
    Burunat E; Diaz Palarea MD; Castro R; Rodriguez M
    Funct Neurol; 1987; 2(3):263-9. PubMed ID: 3692271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist.
    Temlett JA; Quinn NP; Marsden CD; Lataste X; Jaton AL
    Clin Neuropharmacol; 1989 Feb; 12(1):55-9. PubMed ID: 2565766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    J Maine Med Assoc; 1977 Apr; 68(4):134-41, 146. PubMed ID: 845500
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement.
    Brotchie JM
    Curr Opin Neurol; 1997 Aug; 10(4):340-5. PubMed ID: 9266159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute overdose of a new dopamine agonist, CV 205-502.
    Tauveron I; Gesta JM; Jalenques I; Thieblot P
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):551-3. PubMed ID: 7910531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.